Every generation gets a weight-loss breakthrough that feels like it’s finally cracked the code. Right now, that’s GLP-1 medications. Thirty years ago, it was a drug combination called fen-phen. Before that, it was a pregnancy hormone sold in vials and drops, promising the same thing an entire industry has promised for a century: lose the weight without doing the hard part.

It’s worth knowing how those earlier weight-loss histories actually ended — not to scare anyone off GLP-1s, which are a genuinely different and far more rigorously studied category of medication, but because the pattern underneath all three is the same, and it’s worth understanding weight-loss history before you build your own plan around whatever this decade’s breakthrough turns out to be.

Fen-Phen: The 1990s “Miracle” That Cost a Pharmaceutical Giant $22 Billion

In the early 1990s, doctors began prescribing fenfluramine and phentermine together, off-label, as a combination weight-loss treatment. Each drug was individually FDA-approved, but the combination — nicknamed “fen-phen” — was never studied or approved as a pairing. It didn’t matter. Word spread fast that the combination worked dramatically better than either drug alone, and by the mid-90s millions of prescriptions were being written every year.

Then, in 1997, a group of Mayo Clinic physicians published a report in the New England Journal of Medicine describing something alarming: several women who had taken fen-phen needed heart-valve surgery, all showing an unusual pattern of valve damage. The mechanism turned out to be real — fenfluramine was found to cause heart-valve leakage, letting blood flow backward into the chamber it had just left. The FDA pulled fenfluramine from the market within months.

What followed was one of the largest pharmaceutical litigation events in U.S. history. Wyeth (the manufacturer, then known as American Home Products) ultimately set aside roughly $22 billion to cover damages to an estimated 600,000 claimants — starting with a $3.75 billion national settlement trust in 1999, supplemented by another $1.275 billion in 2004, plus an additional $8.5 billion to cover tens of thousands of people who opted out of the class settlement to sue individually. The company sold off billions of dollars in assets to fund it.

The part worth sitting with: fen-phen wasn’t a scam. It worked, in the sense that people lost real weight. The catastrophe wasn’t that the mechanism was fake — it’s that a serious safety risk wasn’t caught until millions of people had already been exposed to it, because the drug combination itself had never been through the rigorous, combined safety trials that would have been required to catch it earlier.

The HCG Diet: Seven Decades of a “Miracle” That Was Just Starvation

If fen-phen’s story is a cautionary tale about real risk hiding behind real results, the HCG diet’s story is almost the opposite — a “miracle” that, when actually studied, turned out to have no mechanism at all.

Human chorionic gonadotropin (HCG) is a hormone naturally produced during pregnancy. In 1954, a British physician named Dr. Albert Simeons published a book, Pounds and Inches, proposing that small daily doses of HCG — paired with an extremely low-calorie diet, typically 500 to 800 calories a day — would redistribute stored fat and suppress hunger in a way no other protocol could match. The diet found renewed popularity roughly every decade since, most recently in the 2000s and 2010s as over-the-counter “homeopathic” HCG drops, sprays, and pellets flooded the market without a prescription.

The research never supported the hormone claim. Mayo Clinic’s assessment is blunt: there’s no proof that HCG itself helps you lose weight. The weight people lost on the protocol came entirely from the 500-to-800-calorie diet — a level of restriction so severe it would produce weight loss with or without the hormone. In 2011, the FDA required HCG diet products to carry warnings stating exactly that, and in the years since, the FDA and FTC have taken repeated joint enforcement action against companies marketing over-the-counter HCG products, calling the weight-loss claims illegal and deceptive. The safety concerns compound the problem: a diet that severe, sustained for weeks, has been linked to gallstones, irregular heartbeat, electrolyte imbalances, and significant nutritional deficiencies — largely because it was never the hormone doing anything. It was near-starvation, marketed as a hormone protocol.

And yet, HCG diet products are still sold today, nearly seventy years after Simeons’ book, to people who’ve never heard this history.

The Pattern That Repeats Every Time

Look at these two weight-loss stories side by side and a pattern emerges that has nothing to do with the specific chemistry involved. Both offered a shortcut around the parts of weight-loss people find hardest — training consistently, eating in a sustainable deficit, being patient. Both delivered real weight-loss, at least temporarily. And both eventually revealed a cost that wasn’t visible at the moment of the “breakthrough” — one a genuine physical danger that took years to surface, the other a total absence of mechanism hiding behind a genuinely brutal diet.

What never changed, across every single one of these eras — 1954, 1996, and today — is the thing this blog keeps coming back to: muscle and strength are built and protected the same way regardless of what’s driving the weight-loss underneath them. Resistance training, adequate protein, and patience were the right prescription in 1996. They were the right prescription in 1954. They’re still the right prescription now.

Where GLP-1s Actually Fit Into This Pattern

This isn’t an argument that GLP-1 medications are “the next fen-phen.” That comparison doesn’t hold up well, and it’s worth saying clearly why. Semaglutide and tirzepatide went through large, randomized, placebo-controlled trials before approval — the exact process fen-phen’s combination never went through — and the data on cardiovascular outcomes, sustained weight-loss, and metabolic markers is genuinely strong and still accumulating. HCG’s problem was that it never had a real mechanism to begin with; GLP-1’s mechanism is well understood, replicated, and the reason the drug class works as well as it does. These are meaningfully different situations, and treating every new weight-loss tool as automatically suspicious because of what happened in 1997 isn’t a fair reading of the evidence either.

What does carry forward is the underlying lesson: whatever tool is driving the weight-loss, the fundamentals of what happens to your body underneath it don’t change. Rapid weight loss pulls from muscle as well as fat unless something specifically protects the muscle. That was true for fen-phen patients, it was true for HCG dieters running a 500-calorie protocol, and it’s true for GLP-1 users today. The medication changes. The biology of what your body does with a calorie deficit does not.

The Bottom Line

Fen-phen taught the industry a hard lesson about combining drugs without adequate safety data, at a cost of roughly $22 billion and, more importantly, real harm to real patients. The HCG diet taught a quieter lesson about how easy it is to mistake near-starvation for a hormonal breakthrough, repackaged and resold for seventy years running. GLP-1 medications are a different, more rigorously studied category — but the constant across all three eras is the same: training and muscle protection were never optional, no matter what decade’s shortcut is doing the weight-loss heavy lifting.

If you want a plan built around the fundamentals that have held up across every one of these eras — not the trend of the moment — reach out to Coach Erik at Viking Athletics in West Hartford, CT.

Sources referenced: Forbes, “The $22 Billion Gold Rush”; ABC News, “Judge OKs $3.75 Billion Fen-Phen Payment”; Mayo Clinic, “HCG diet: Is it safe and effective?”; Drugs.com / FDA, “HCG Diet Products Are Illegal”